Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine weather Lectranal is effective in treatment of seasonal allergic rhinitis symptoms.
| Condition | Intervention | Phase |
|---|---|---|
|
Seasonal Allergic Rhinitis |
Dietary Supplement: Lectranal Dietary Supplement: placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms |
- changes in SARS (seasonal allergic rhinitis symptoms) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- changes in Mini RQLQ (mini rhinoconjunctivitis quality of life questionnaire) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- changes in specific IgE [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- changes in specific IgG [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- Prick test change [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- change in eosinophilia in nasal secretion [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 48 |
| Study Start Date: | April 2007 |
| Study Completion Date: | November 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: 2 |
Dietary Supplement: placebo
Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
|
| Active Comparator: 1 |
Dietary Supplement: Lectranal
Dosage form: capsule 1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks Other Name: Lectranal
|
Detailed Description:
Patients allergic to the specific pollen are divided into two groups randomly. One group is being administered Lectranal and the other group is being administered placebo during the period of 6 weeks in season of the pollen. Methods used for evaluation are: SARS questionnaire(seasonal allergic rhinitis symptoms), Mini RQLQ (mini rhinoconjunctivitis quality of life questionnaire) skin Prick test, specific IgE and IgG, eosinophilia in nasal secretion. Methods used for follow up safety include side effects report, physical examination and vital signs.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- history of seasonal allergic rhinitis symptoms to pollen
- positive skin prick test to pollen
- negative history of seasonal allergic asthma
- male or female older than 18
- female participants must use appropriate contraception
- able to comply to study procedures
Exclusion Criteria:
- pregnancy
- alcohol or drug abuse
- subject receiving antihistamines , immunotherapy or on hyposensibilisation
Contacts and Locations
More Information
Publications:
| Responsible Party: | Neven Tudoric MD PhD, Dubrava University Hospital, Zagreb, Croatia |
| ClinicalTrials.gov Identifier: | NCT00460538 History of Changes |
| Other Study ID Numbers: | MIL-002 |
| Study First Received: | April 13, 2007 |
| Last Updated: | April 2, 2010 |
| Health Authority: | Republic of Croatia: Ethic Committee of Dubrava University Hospital |
Keywords provided by Milsing d.o.o.:
|
Seasonal allergic rhinitis lectranal allergy |
Additional relevant MeSH terms:
|
Rhinitis, Allergic, Seasonal Rhinitis Nose Diseases Respiratory Tract Diseases Respiratory Hypersensitivity |
Otorhinolaryngologic Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Respiratory Tract Infections |
ClinicalTrials.gov processed this record on May 16, 2013